Aclarion, Inc. (ACON)
NASDAQ: ACON · Real-Time Price · USD
6.14
-0.81 (-11.65%)
At close: Dec 5, 2025, 4:00 PM EST
6.26
+0.12 (1.95%)
After-hours: Dec 5, 2025, 5:48 PM EST
Aclarion Revenue
Aclarion had revenue of $18.94K in the quarter ending September 30, 2025, with 31.48% growth. This brings the company's revenue in the last twelve months to $67.48K, up 36.91% year-over-year. In the year 2024, Aclarion had annual revenue of $45.72K, down -39.36%.
Revenue (ttm)
$67.48K
Revenue Growth
+36.91%
P/S Ratio
52.99
Revenue / Employee
$11,247
Employees
6
Market Cap
4.12M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ACON News
- 3 days ago - Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S. - GlobeNewsWire
- 6 weeks ago - Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH - GlobeNewsWire
- 2 months ago - Aclarion to Present at the LD Micro Main Event XIX - Newsfile Corp
- 5 months ago - Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum - GlobeNewsWire
- 7 months ago - Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site - GlobeNewsWire
- 7 months ago - Aclarion Announces Texas Back Institute as New CLARITY Trial Site - GlobeNewsWire
- 7 months ago - Aclarion Announces Commercial Agreement with Spine Institute of Louisiana - GlobeNewsWire
- 8 months ago - Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025 - GlobeNewsWire